Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

magazine

Will GlaxoSmithKline continue to struggle with asthma product sales?

Lower volumes and prices have hit the pharma giant's asthma product sales in the past
Thursday 20 Jul 2017 Author: Lisa-Marie Janes
Week Ahead

Wednesday 26 July

Investors should check whether sales of GlaxoSmithKline’s (GSK) asthma treatments have further declined when it reports half year results on 26 July. In April, sales of its Advair/Seretide products in the US fell due to lower volumes and prices.

Generic competition against Advair has been restrained after the US Food and Drug Administration prevented US rival Mylan from launching its Wixela Inhub product in its current form.

‹ Previous2017-07-20Next ›


20 Jul 2017

Download PDF

Page flip version

Important information:

These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.

Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.

Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.

The Shares team
Disclaimer

Issue contents

Big News

Editor's View

Feature

Great Ideas

Investment Trusts

Larger Companies

Main Feature

Money Matters

Smaller Companies

Story In Numbers

Under The Bonnet

Week Ahead

Magazine archive


24 Apr 2025
17 Apr 2025
10 Apr 2025

3 Apr 2025
27 Mar 2025
20 Mar 2025

13 Mar 2025
6 Mar 2025
27 Feb 2025